ioveraº

Search documents
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
Globenewswire· 2025-07-24 12:00
Core Viewpoint - Pacira BioSciences, Inc. is set to report its second quarter financial results on August 5, 2025, and will host a live conference call and webcast following the release [1]. Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3]. - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3]. - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3]. - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3]. - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3].
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Globenewswire· 2025-05-14 12:00
Core Insights - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [2] - The company will participate in two upcoming healthcare conferences, providing opportunities for analysts to engage with its leadership [1][3] Company Overview - Pacira has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic approved for various postsurgical pain management applications [2] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [2] - ioveraº, a handheld device for drug-free pain control using cold temperature [2] - The company is also developing PCRX-201, a novel gene therapy aimed at treating prevalent diseases like osteoarthritis [2]
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
Globenewswire· 2025-04-29 12:00
Core Viewpoint - Pacira BioSciences, Inc. is set to report its first quarter financial results on May 8, 2025, and will host a live conference call following the release [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3] - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]